Indirubin Targets PI3K–AKT Signaling in Acute Lymphoblastic Leukemia: Integrated Computational and Experimental Evidence
Pharmaceutical Sciences and Drug Design · 2026 · 6 (1) · 19-38
DOI: 10.51847/cnpn19mv34 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Sciences and Drug Design, 2026. Verfasst von Ravi Kumar und 4 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Kumar, R., Sharma, N., Deshmukh, A., Nair, A., & Pillai, M. (2026). Indirubin Targets PI3K–AKT Signaling in Acute Lymphoblastic Leukemia: Integrated Computational and Experimental Evidence. Pharmaceutical Sciences and Drug Design, 6(1), 19-38. https://doi.org/10.51847/cnpn19mv34
Vancouver
Kumar R, Sharma N, Deshmukh A, Nair A, Pillai M. Indirubin Targets PI3K–AKT Signaling in Acute Lymphoblastic Leukemia: Integrated Computational and Experimental Evidence. Pharmaceutical Sciences and Drug Design. 2026;6(1):19-38. doi:10.51847/cnpn19mv34
BibTeX
@article{Kumar2026,
author = {Kumar, Ravi and Sharma, Neha and Deshmukh, Aniket and Nair, Arjun and Pillai, Meera},
title = {Indirubin Targets PI3K–AKT Signaling in Acute Lymphoblastic Leukemia: Integrated Computational and Experimental Evidence},
journal = {Pharmaceutical Sciences and Drug Design},
year = {2026},
volume = {6},
number = {1},
pages = {19--38},
doi = {10.51847/cnpn19mv34}
}
EUVIMED